Season One of Surfing The NASH Tsunami
Wayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exciting paths for new agents and non-invasive testing
Louise Campbell questions the implication of APASL and ALEH endorsing “MAFLD” as Fatty Liver Disease nomenclature and Stephen Harrison discusses behind-the-scenes activities to resolve this issue
Joern Schattenberg discusses the public health implications of German newspapers beginning to discuss Fatty Liver Disease
44.1 – 2020 Year in Review with Ian Rowe: Simplifying NASH Diagnostics Saves Money, Improves Satisfaction
Ian Rowe discusses how streamlined use of ELF, FIB-4 and FibroScan improves cost effectiveness and patient satisfaction associated with NASH screening
Guests Ian Rowe, Joern Schattenberg and Wayne Eskridge join the Surfers to discuss key lessons learned in 2020 about Patient Treatment and Perspectives
Roger Green discusses why despite widespread concerns, FDA’s Complete Response Letter to Intercept did not cripple progress in NASH drug development.
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
Stephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial drug approvals
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in Fatty Liver Disease
Mazen Noureddin describes a year in which biopsy’s shortcomings are revealed at the same time as non-invasive testing becomes better and produces more robust data
Vlad Ratziu discusses a “boiling hot” field of emerging NASH drugs and “particularly rich” data coming from no-invasive diagnostic testing
The Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics
Donna Cryer and Global Liver Institute Director of Policy Andrew Scott return to discuss their 2021 US NASH Action Plan, garnering support for the new COVID-19 vaccines and the importance of aligning stakeholders with Stephen, Louise and Roger.
Episode 41- Policy 1: The Liver Policy Agenda Has Experienced Surprising Success in the Last Four Years
Donna Cryer and Global Liver Institute Director of Policy Andrew Scott join Stephen, Louise and Roger to discuss the policy progress liver disease and NASH have made in the last four years.
Dr Ian Rowe and Prof. Dr. Jörn M. Schattenberg joins the Surfers to explore the relationship between NAFLD and CVD in light of recent work questioning the strength of links between the two
Guest Ian Rowe and Kris Kowdley join the Surfers to discuss how the 2nd COVID wave and arrival of the vaccine are likely to affect patient treatment and clinical development
Vlad Ratziu and Joern Schattenberg join the Surfers to wrap up our conversation about this year’s AASLD meeting
Mary Rinella joins the Surfers for a final day of AASLD 2020 reviewing focusing equally on lessons in drug development and the crying need for social and dietary education, particularly for parents and children.
Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs
Ep 35 – Saturday at TLMdX 2020 from AASLD: Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint
Manal Abdelmalek joins the Surfers to review some of Saturday’s most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic
Prof. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recent drug trial failures.
Stephen Harrison, Roger Green and our guest Surfer, Dr. Manal Abdelmalek, identify pivotally important presentations and posters from The Digital Liver Meeting 2020
Louise Campbell, Donna Cryer and Naim Alkhouri identify pivotally important presentations and posters from The Digital Liver Meeting 2020
Guest Surfer and regular listener Dr. Ian Rowe joins the Surfers to discuss how everyday patient treatment in the clinic once was and how COVID-19 and the news we discuss weekly on SurfingNASH have changed practice.
On the six-month anniversary of SurfingNASH’s first episode, the Surfers stop to consider how much has changed for NASH stakeholders since April
Matt Kelly, Chief Innovation Officer at Perspectum, Ltd., joins the Surfers to the discuss early findings from the COVERSCAN study which looks at the relationship between COVID-19 infection and major end organ systems.
Stephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news
The Surfers discuss four issues that are likely to affect how our thinking about NASH diagnosis, education, and treatment might evolve over the next three months.
“Beyond the Biopsy”— How NASH Therapy Will Improve When Non-Invasive Tests Become The Standard – Ep 26
The Surfers discuss the Global Liver Institute’s campaign to educate and motivate key stakeholder groups on the value of non-invasive liver testing.
The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.
Professors Joern Shcattenberg and Vlad Ratziu join the Surfers to discuss the lessons and findings we can take away from Digital ILC 2020
Day Three into EASL Digital ILC 2020
Day Two into EASL Digital ILC 2020. Drugs in development and diagnostics show promise but healthcare has far to go in identifying and treating patients in need.
Day One into EASL Digital ILC 2020
The group discusses the plusses and minuses of digital conferences compared to traditional in-person events.
Patient advocates envision future digital technologies that can provide tremendous benefit to them and how government agencies provide support for better disease knowledge and care
Patient advocates discuss how doctors and other providers can serve patient needs better
FOCUS: More of the presentations that will make NASH/NAFLD news at the Digital International Liver Congress later this month
How passionate providers (nurses, dieticians, and physicians) can motivate patient lifestyle changes.
FOCUS: Some of the presentations that will make NASH/NAFLD news next month
NASH is not merely a byproduct of obesity.
FOCUS: Three sets of tools that will improve NASH disease understanding
Decoding the message of Intercept’s Complete Response Letter
CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications
What would create greater value for patients and providers?
SurfingNASH celebrates a growing and increasingly important global event for the Fatty Liver community.
Room for improvement
Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials
Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s)
Clinical trial results that are changing how we look at NASH
Three possible scenarios for development of the NASH market.
Critical considerations for companies developing NASH drugs
What investors want to know about NASH development during the pandemic.
Navigating NAFLD/NASH clinical trials through the pandemic